Effects of Shenkang for chronic kidney disease: a propensity score matched with network pharmacology analysis

Shenkang (SK) is a widely used formula for treating chronic kidney disease (CKD) since the 1990s. However, the associations of SK use with the long-term outcome among CKD patients have not been validated in real‐world study. This single-center retrospective study included outpatients with CKD from 1 January 2013, to 31 December 2023. Patients who received SK were compared with control group after propensity score matching. A total of 2,463 patients met the inclusion criteria, with 546 matched pairs. The SK group had a significantly lower risk of end-stage renal disease (adjusted hazard ratios = 0.83, 95% confidence interval: 0.70–0.98; p = 0.030), and the cumulative event of end-stage renal disease was significantly lower in the SK group than in the control group (p = 0.027). The estimated glomerular fitration decline in SK group was also significantly slower than those in control group (p in vivo and in vitro is required.